How to buy Metacrine (MTCR) stocks in Canada
Learn how to easily invest in Metacrine stocks.
Metacrine is a biotechnology business based in the US. Metacrine stocks (MTCR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.84 – a decrease of 12.63% over the previous week. Metacrine employs 35 staff and has a trailing 12-month revenue of around $2.2 million.
How to buy shares in Metacrine
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MTCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Metacrine stock price (NASDAQ:MTCR)Use our graph to track the performance of MTCR stocks over time.
Metacrine shares at a glance
|Latest market close||$0.49|
|52-week range||$0.51 - $11.00|
|50-day moving average||$1.07|
|200-day moving average||$2.87|
|Wall St. target price||$8.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.27|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Metacrine stock?
Metacrine price performance over time
|1 week (2022-01-14)||-12.60%|
|1 month (2021-12-22)||-46.04%|
|3 months (2021-10-22)||-69.82%|
|6 months (2021-07-22)||-84.82%|
|1 year (2021-01-22)||-94.85%|
|2 years (2020-01-18)||N/A|
|3 years (2019-01-18)||N/A|
|5 years (2017-01-18)||N/A|
|Revenue TTM||$2.2 million|
|Gross profit TTM||$-26,790,000|
|Return on assets TTM||-40.52%|
|Return on equity TTM||-81.9%|
|Market capitalisation||$23.6 million|
TTM: trailing 12 months
Metacrine share dividends
We're not expecting Metacrine to pay a dividend over the next 12 months.
Metacrine, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. .
Stocks similar to Metacrine
Metacrine in the news
Markets are expected to remain on edge as the Fed meets in the week ahead
Netflix quietly admits streaming competition is eating into growth
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Frequently asked questions
More guides on Finder
How to buy Aritzia stock in Canada
CI Direct Trading review
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
Shiba Inu (SHIB) price, history and performance
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
Pendle (PENDLE) price, chart, coin profile and news
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
The ChampCoin (TCC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.